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A B S T R A C T
Skin protects body from continual attack by microbial pathogens and environmental factors. Such
barrier function of skin is achieved by multiple components including immune system, which is mainly
regulated by lymphocytes. T lymphocytes (T cells) that express T cell receptor (TCR) a and b chains (abT
cells) control the strength and the type of immune response. CD4T cell population consists of helper T
(Th) cell-subsets and immunosuppressive regulatory T (Treg) cells. Th1 cells produce IFN-g and protect
against intracellular pathogens. Th2 cells produce IL-4 family cytokines and participate in allergic skin
diseases, including atopic dermatitis (AD). Th17 cells secrete IL-17, recruit granulocytes to ﬁght against
extracellular microorganisms, and play a role in psoriasis and AD. Th22 cells produce IL-22 that activates
epithelial cells and mediates acanthosis in psoriasis and AD. On the other hand, Foxp3+ Treg cells
attenuate immune responses partly via TGF-b or IL-10. Tissue resident memory T (Trm) cells in the
skin—most of which are epidermal CD8T cells—constitute the ﬁrst line of the defense against repeated
infections. CD8 T cells are also engaged in psoriasis, lichen planus, and drug eruptions. Skin harbors
innate-like abT cells such as natural killer T (NKT) cells as well, whose function is not fully revealed.
Understanding these abT cells helps to comprehend skin diseases.
 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights
reserved.
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The barrier function of skin includes immune system, which
evokes innate and adaptive immune responses, participated by not
only lymphocytes but also keratinocytes and endothelial cells.
Immune system is built of distinct types of cells including
lymphocytes such as T lymphocytes (T cells), B lymphocytes (B
cells), and natural killer (NK) cells, which determine the speciﬁcity
and the type of immunity. T cells can also introduce unrespon-
siveness to particular antigens, i.e., immunological tolerance. This
review summarizes characteristics of skin abT cells—T cells that
express T cell receptor (TCR) a and b chains.
2. The three features of abT cells in the skin
The skin is an essential immune organ [1]. One million T cells
exist in every square centimeter of normal skin, adding up to over
20 billions in the entire human skin, estimated to be twice the
number of T cells in circulation [2]. There are three major features
in abT cells in the skin (Fig. 1) [3]. Firstly, most of the skin T cells
are memory cells expressing CD45RO and other memory markers.
Secondly, tropism of T cells toward skin is determined by CCR4,
CCR10, and CLA (cutaneous lymphocyte antigen). CLA, a modiﬁed
version of PSGL-1 (P-selectin glycoprotein ligand-1), binds to
E-selectin (CD62E) on endothelium of post-capillary venules in
dermis [4]. CCR4 is a receptor for MDC (macrophage-derived
Fig. 1. The three features of abT cells in the skin. Skin abT cells have three
characteristics: memory phenotype, skin tropism, and locality of subsets. (1)
Essentially all of the skin abT cells are memory cells. They express CD45RO and
CD44 (at a high level) whereas neither CD62L nor CCR7 is expressed. (2) Skin
tropism is determined by CLA (a ligand for CD62E expressed on the endothelial cells
(ECs) of post-capillary venules in the skin), CCR4 (a receptor for TARC), and CCR10 (a
receptor for CTACK). Keratinocyte (KC) produces TARC and CTACK. (3) Locality is
different between CD8 and CD4T cells. Skin CD8T cells, which are resident memory
cells, localize in epidermis. They are rigged with cytotoxic molecules and poised
themselves to attack intruders. Skin CD4T cells, which are effector memory cells or
resident memory cells, are distributed perivascular area in dermis. Treg cells
(represented by R in ﬁgure) also reside in dermis in steady state.chemokine or CCL22) and TARC (thymus and activation-regulated
chemokine or CCL17). MDC is produced by skin macrophages and
keratinocytes, while TARC is secreted by keratinocytes. CCR10
mediates chemotaxis toward CTACK (cutaneousT cell-attracting
chemokine or CCL27), which is made by keratinocytes [4]. Thirdly,
there is a division of locality among subsets. Dermis embraces the
majority of abT cells, most of which are CD4T cells occupying
perivascular area. Epidermis contains only a few of abT cells,
which are essentially CD8 tissue-resident memory T (Trm) cells.
These skin Trm cells protect the whole body from infection [5].
3. Generation of skin-homing T cells
How T cells acquire skin-tropism is a cardinal question [6]. The
‘‘memory’’ phenotype of skin-homing T cells suggests importance
of activation step in obtaining skin-tropism.
Activation liberates naı¨ve T cells from recirculation within
secondary lymphoid organs by reducing expression of CD62L,
CCR7 and S1P1, followed by induction of different homing
receptors such as PSGL-1, CD44, CCR5, and CXCR3 [4,6]. Skin-
homing T cells are further endowed with skin-tropism by CLA,Table 1
Features of memory T cells.
Naı¨ve Central
memory
Multiplication Slow Prompt 
Cytokine secretion No Poor 
CD44 No or low Yes 
CD62L (L-selecting)* Yes Yes 
CCR7 * Yes Yes 
CD127 (IL-7Ra) Varied Yes 
CD69 No No 
CD103 (Integrin aE) No No 
CD11a Varied Varied 
Distribution LN, Sp, PB LN, Sp, PB, 
Migration Yes Yes 
Notes. Resident memory CD8T cells distribute in the skin, gut, vagina, salivary glands,
peripheral tissue except for the lung. Resident memory T cells are suggested to be supp
enhanced by repeated immunization.
Symbols and abbreviations: *, lymphoid homing molecules; LN, lymph nodes; Sp, spleCCR4 and CCR10, as described earlier. Dermal DCs help this
endowment by metabolizing sun-light induced epidermal vitamin
D3 to 1,25(OH)(2)D3, which imprints T cells to express CCR10 [4].
However, how and where such activated T cells fully equip
themselves as skin-homing T cells remains unknown.
Clearance of pathogens triggers apoptosis of activated T cells,
leaving long-lived memory T cells such as central memory T (Tcm),
effector memory T (Tem), and tissue-resident memory T (Trm)
cells (Table 1) [4]. Tcm cells express CCR7 and CD62L and
recirculate secondary lymphoid organs. Skin T cells include CD4
Tem, some CD4 Trm cells in the dermis, and sessile CD8 Trm cells in
the epidermis [3]. Neither the relationship between these memory
T cells nor the molecular cues that conduct development of skin
memory T cells is fully disclosed yet [6].
4. Subsets of abT cells
CD4T cells and CD8 T cells are the major two lineages of abT
cells. Skin CD4T cells consist of diverse helper T (Th) cells including
Th1, Th2, Th17, Th22, Th9, and Treg cells (immunosuppressiveTEffector
memory
Resident
memory
Slow Poor
Prompt Prompt
Yes Yes
No No
No No
Yes Varied
No Yes
No Yes
Varied Yes
BM Sp, PB, peripheral tissue Peripheral
tissue
Yes No
 lung, and brain. Resident memory CD4T cells are fewer and difﬁcult to prove in
orted by the peripheral tissues in the absence of antigen stimulation although be
en; PB, peripheral blood; BM, bone marrow.
Table 2
Subsets of CD4T cells associated with skin.
Subset Inducing
cytokine
Master
regulator
Effector cytokine Inhibitors Function Host defense Pathology
Th1 IFN-g, IL-12 T-bet INF-g IL-4 Activation of MF, Ig
class switch to
IgG1/G3 (human)
or IgG2a/G3
(mouse)
Intracellular
pathogens
Granulomatous
disease
Th2 IL-4 GATA3 IL-4, -5, -10, -13 IFN-g Activation of MC,
Bas, Eos, M2MF,
barrier function, Ig
class switch to IgE
Helminths AD
Non-pathogenic
Th17
IL-6, TGF-b RORgt IL-17, IL-10 IL-2, -4, IFN-g,
Foxp3, T-bet
Recruitment of
neutrophils (?)
Undeﬁned Undeﬁned
Pathogenic Th17 IL-6, IL-23,
IL-1b, TGF-b3
RORgt, T-bet IL-17, IL-22,
IFN-g, GM-CSF
Ditto and TGF-b1(?) Recruitment of
neutrophils
Extracellular
bacteria and fungi
Psoriasis, RA,
MS, AD
Th22 IL-6, TNF-a Undeﬁned IL-22 TGF-b1 Induction of
defensins
Klebsiella
pneumoniae
Psoriasis, AD,
chloracne
Th9 IL-4, TGF-b PU.1, IRF4 IL-9 Undeﬁned Activation of skin-
tropic T cells to
produce IFN-g, IL-9,
-13, and -17
Candida albicans Allergy, psoriasis
Treg IL-2, TGF-b Foxp3 TGF-b, IL-10,
IL-35
IL-6, RORgt,
HIF1a
Peripheral
tolerance, tuning of
immune response
Tuning of
inﬂammation
Cancer, chronic
infection
Tr1 IL-27, TGF-b c-Maf IL-10 Undeﬁned Ditto Ditto Undeﬁned
Th3 Undeﬁned Undeﬁned TGF-b Undeﬁned Ditto Ditto Undeﬁned
LAG3 Treg Undeﬁned Undeﬁned IL-10 Undeﬁned Ditto Ditto Undeﬁned
MF, macrophages; M2MF, M2 macrophage; MC, mast cells; Bas, basophils; Eos, eosinophils; AD, atopic dermatitis; Ig, immunoglobulin; RA, rheumatoid arthritis; MS,
multiple sclerosis; Ditto, same as above.
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cells, which express invariant TCRs and share functions with
natural killer (NK) cells, a subset of innate lymphocytes.
5. CD4T cells
The ﬁrst two subsets identiﬁed were type 1 helper T (Th1) cells
and Th2 cells, followed by IL-17-producing Th17 cells, which
mediate autoimmune diseases that had been attributed to Th1
cells. Furthermore, other unique subsets such as the IL-9-
producing Th9 cells, IL-22-producing Th22 cells, and germinal
center forming follicular helper T (Tfh) cells have gained
recognition in recent years as well. CD4T cells include immuno-
suppressive subsets: Foxp3+ Treg cells, Tr-1, and Th3 cells. A
question to whether these CD4 or CD8T cell-subsets represent
terminally differentiated state or they just reﬂect certain aspect of
transient states remains to be solved [7].
5.1. Th1 cells
Th1 cells dominate during the early phase of contact dermatitis
[8]. They secrete IFN-g and protect against intracellular pathogens
such as Mycobacteria and viruses. Expression of IL-12 receptor b1
and b2 subunits, IL-18 receptor, CXCR3, and CCR5 is characteristic
to Th1 cells, function of which can be ascribed to IFN-g.
Differentiation of Th1 cells is regulated by IFN-g in synergy with
IL-12, IL-18, and type I IFN, i.e., IFN-a and b. IL-12 activates signal
transducer and activator of transcription (STAT) 4, a modiﬁer of
Th1-related genes such as IFNG, IL12R, and IL18R. IFN-g activates
STAT1 and reinforces Th1 cell-differentiation. Activated STAT4 and
STAT1 induce expression of T-bet, encoded by TBX21 gene (the
master regulator for Th1 cells) [9].
5.2. Th2 cell
Th2 cells play a central role in atopic diseases such as asthma,
chronic rhinosinusitis, AD, and food allergy. They secrete IL-4, IL-5,
IL-13, IL-24 (an antitumor cytokine of IL-10 family), IL-25 (IL-17E,an IL-17 family cytokine that ampliﬁes allergic responses) and
IL-31 (a pruritus-inducing IL-6 family cytokine). Isotype class-
switching to IgE, mediated by Th2 cells, contributes to host defense
against parasitic worms. Full activation of Th2 cells is achieved by
collaboration with epithelial cells—keratinocytes in the skin—and
group 2 innate lymphoid cells (ILC2s) [10].
Th2 cells regulate the acute- and late-phase allergic reactions
mediated by IgE and eosinophils, respectively. IgE-production is
stringently controlled by at least two steps. The ﬁrst is mediated by
Th2-cytokines, IL-4 and IL-13, which stimulate B cells through
STAT6 to produce e germline transcripts, a prerequisite for class-
switch recombination. The second is conducted by CD40/CD40
ligand through cell-to-cell contact between Th2 and B cells, leading
to completion of recombination of IgE locus [11]. IgE activates mast
cells and basophils, both of which initiate the early-phase allergic
response. The late-phase response is mediated by eosinophils, of
which maturation, migration, activation, and survival are modu-
lated by Th2-cytokines.
Impairment of skin barrier irritates keratinocytes to produce IL-
25, IL-33 (an IL-1 family alarmin), and TSLP (thymic stromal
lymphopoietin) [10]. These cytokines activate ILC2s that promptly
produce IL-5, IL-9, and IL-13, leading to activation of Th2 cells [10].
Th2-cytokines are speculated to damage the skin barrier further;
IL-4 and IL-13 reduce ﬁlaggrin expression of human keratinocytes,
in vitro [12]; IL-31 induces pruritus, which triggers scratch-
behavior leading to further barrier damages [12]. Therefore, atopic
skin diseases are complexed with a trinity of barrier abnormality,
allergy/immunology, and pruritus [12].
Th2 cells may play a role in tumor immunity because IL-24,
melanoma differentiation-associate antigen 7, is known to induce
apoptosis of tumor cells [13]. Contribution of Th2 cells in skin
tumors awaits further investigation.
5.3. Th17 cells
Th17 cells are involved in psoriasis and AD. This subset can be
divided in non-pathogenic and pathogenic Th17 cells, or ‘‘Th17(b)’’
and ‘‘Th17(23)’’ cells, respectively [14]. IL-23 activates Th17 cells
Table 3
Representative cytokines produced by Th17 cell-activated keratinocytes.
Cytokine Name Suggested roles
Interleukin IL-32 Viral infections and Wegener’s
granulomatosis
IL-36 Activation of innate response as an IL-1
family interleukin and a possible cause
of psoriasis
Chemokine CXCL1 Trafﬁcking of immune cells
(neutrophils in particular)
CCL20 Trafﬁcking of CCR6+ cells including
Th17 cells
Peptide HBD-2 A beta defensin that attracts mast cells
and neutrophils
S100A7 Killing of E. coli; increased in psoriasis
S100A15 Similar role as S100A7
S100A7 and S100A15 are also called psoriasin and koebnerisin, respectively.
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psoriasis, rheumatoid arthritis, multiple sclerosis, and AD. Th17 cells
protect against bacteria and fungi by controlling neutrophils [14].
Discovery of Th17 cells originates from studies on experimental
autoimmune encephalomyelitis (EAE, a mouse model of multiple
sclerosis) using gene-targeted mice for Th1-cytokine IL-12 (a
heterodimer of p35 and p40), which came to a paradoxical
conclusion; p40-/- mice were resistant to EAE, as expected, while
p35-/- became more susceptible than wild-type. This led to
identiﬁcation of IL-23 (a heterodimer of p19 of IL-23 and p40 of IL-
12) and Th17 cells.
Function of Th17 cells is ascribed to IL-17, which summons
neutrophils that besiege extracellular bacteria and fungi. Defense by
Th17 cells is oriented to mucocutaneous surface than to the whole
body, and its known targets are Staphylococcus aureus, Klebsiella
pneumoniae, and Candida albicans [14]. Phenotype of the autosomal
dominant hyper IgE syndrome (HIES or ‘‘Job’s syndrome’’) is
explained by dysfunctional Th17 cells due to mutations of STAT3,
a signal transducer that is activated by IL-6 and IL-23 [14].
Non-pathogenic Th17—Th17(b)—cells express IL-17A, IL-17F,
IL-10, CCL20, and CXCR6, and are differentiated by combination of
IL-6 and TGF-b1. Non-pathogenic Th17 cells become pathogenic
after exposure to IL-23. Combination of IL-1b, IL-6, and IL-23
induces pathogenic Th17—Th17(23)—cells, which express IL-22,
CCL9, and CXCR3 in addition to IL-17A and IL-17F [14]. Thus, IL-23
occupies a central role in Th17-mediated pathogenicity.
Keratinocytes regulate differentiation and activation of Th17
and Th22 cells. Irritated keratinocytes produce IL-1b and IL-6,
which stimulate LCs and dermal DCs to produce IL-23 and to
migrate to regional lymphnodes; where Th17 and Th22 cells are
differentiated [15]. Skin-homing Th17 and Th22 cells produce IL-
17A, IL-17F, IL-22, and TNF-a, which stimulate keratinocytes to
produce cytokines such as IL-33, IL-36, CXCL1, CCL20, and anti-
bacterial peptides (Table 3).
Psoriasis is a prototype of Th17-mediated skin disease [16].
Ustekinumab—an anti-IL-12p40 monoclonal antibody—was origi-
nally chosen because IFN-g-producing Th1 and Tc1 cells (CD8T
cells) are abundant in psoriatic lesions. However, it is now
appreciated that neutralization of IL-12p40 targets IL-23/IL-17 axis
of Th17-mediated pathway [17]. An anti-human IL-17A monoclo-
nal antibody was effective for psoriasis in a clinical study [18]. The
role of IFN-g-producing lymphocytes in psoriasis remains
unknown.
Th17 cells seem to affect AD, a representative Th2-mediated
skin disease. Firstly, number of Th17 cells was increased in
peripheral blood and skin lesion of AD in proportion to the disease
severity [19]. Secondly, IL-17A-deﬁcieny attenuates skin inﬂam-
mation and production of IL-4 and hapten-speciﬁc IgG1 and IgE in
response to repeated hapten exposure, a murine model of AD [20].
Finally, IL-17A promotes Th2 cell-differentiation in vitro [20].
Therefore, Th17 cells and other IL-17-producing cells are suggested
to take part in AD.
5.4. Th22 cells
Skin-homing Th22 cells express CCR4, CCR6, and CCR10 [21].
Function of this subset is ascribed to IL-22: an IL-10-familyTable 4
Subsets of Foxp3+ Treg cells.
Subset Development Precursor Role of T
tTreg Thymus Thymocytes at DP stage Survival o
pTreg Extra-thymus CD4T cells Induction
RA, retinoic acid; DP, CD4/CD8 double positive.
a Foxp3+ T cells, induced by TGFb in vitro, do not express Helios, whereas injection cytokine, which operates as pro- and anti-inﬂammatory ways, and
is also produced by Th1, Th17, and gdT cells in humans. IL-22
activates epithelial innate immune responses, which can be
protective or detrimental. An example of pathogenic effect is
epithelial hyperplasia in psoriasis. IL-22 promotes squamous cell
carcinoma of immunocompromised patients [21]. IL-22 and Th22
cells are involved in various skin diseases including psoriasis
vulgaris, AD, contact dermatitis, and scleroderma [21].
Th22 cells are induced by IL-6 and TNF, both of which are
produced by plasmacytoid DCs [21]. Speciﬁc transcription factor is
not deﬁned for Th22 cell-differentiation while aryl hydrocarbon
receptor (AhR) and RORgt are at least important for production of
IL-22 [22]. Th22 and Tc22 (IL-22-producing CD8T) cells accumulate
in lesions of psoriasis and AD [21]. Lipid antigen (presented on
CD1a by LCs) stimulates Th22 cells and mediates acanthosis [21].
Number of Th22 cells was increased in a dioxin-intoxicated
patient, although how IL-22 contributes to the dioxin-induced
chloracne remains unknown [23].
5.5. Th9 cells
Th9 cells are induced from Th2 or naı¨ve T cells by IL-4 and TGF-
b [24]. In humans, Th9 cells in blood and tissues are skin-tropic or
skin-resident memory cells that produce TNF-a, granzyme B, and
IL-9 but not cytokines common to other helper T cells, and are
speciﬁc for Candida albicans [25]. Human Th9 cells transiently
produce IL-9, which maximizes production of IFN-g, IL-9, IL-13,
and IL-17 by skin-tropic T cells [25]. IL-9-producing cells are
increased in psoriasis and AD [25].
5.6. Foxp3+ regulatory T cells
Foxp3+CD4+ regulatory T (Treg) cells are immunosuppressive
subset, which contains thymus-derived (tTreg) and peripherally
induced (pTreg) cells (Table 4) [26]. Discovery of Foxp3 promoted
investigation of this subset on a molecular basis [27–30]. Defects in
Treg cells may cause various skin disorders including psoriasiform
dermatitis, eczematous dermatitis, cheilitis, nail dystrophy, serum
hyper-IgE, eosinophilia, alopecia areata, urticaria, and bullous
pemphigoid, because these symptoms are observed in patientsGF-b Role of RA Helios
f precursors Not shown Yes
 of Foxp3 Enhancement of Foxp3 induction Controversiala
of peptide agonist induces Helios+Foxp3+T cells from naı¨ve T cells in vivo.
Table 5
Modes of suppression by Treg cells.
Mode Note
Humoral Immunosuppressive cytokines; TGF-b, IL-10, and IL-35 (heterodimer of EBI3 and
p35 subunit of IL-12)
Absorption of IL-2 (aT cell growth factor) by CD25 (IL-2 receptor a) expressed on Treg cells
Generation of adenosine (a strong immunosuppressive product) by CD39 and CD73 expressed on Treg cells
Cell-contact-dependent Transmission of intracellular cyclic AMP (an inhibitor of cell proliferation) in Treg cells into target cells through gap junction
Killing of antigen presenting cells (APCs) by granzyme or perforin
Eclipsing of APCs by strong interaction between CTLA4 on Treg cells and CD80/CD86 on APCs, thereby edging out naı¨ve T cells
Modiﬁcation of APC Down-modulation of CD80/CD86 on APCs through the interaction with CTLA4 on Treg cells
Induction of IDOa in APCs through interaction of CD80/CD86 with CTLA4 on Treg cells
a IDO, indoleamine 2,3-dioxygenase, catabolizes tryptophan to kinurenin, which is very toxic to T cells, thereby inhibiting T cell response.
Table 6
Summary of skin CD8 T cells.
Features Note
Effector molecules IL-17, IL-22, or other cytokines shared with Th1
and Th2. Such CD8T cells are called Tc1, Tc2, Tc17,
or Tc22. Perforin, granulysin, and Fas ligand,
which induce apoptosis of target cells.
Surface markers CD8 (CD8aa, in a subset), ligands or P- and E-
selectin, PSGL-1 (CD162, a ligand for P-, E-, and L-
selectin), CLA (a ligand for E-selectin), CD43 (a
ligand for E-selectin), CD44 (a memory marker
and a receptor for hyaluronic acid), CD103
(integrin aE, in a subset)
Function Prompt response to antigens as resident memory
T cells and killing or tumor cells
Relation to skin disease Contact dermatitis, psoriasis, graft versus host
disease, drug eruption, ﬁxed drug eruption
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endocrinopathy, enteropathy, X-linked syndrome), a genetic
disorder caused by Foxp3 mutation [31]. Treg cells are speculated
to relieve inﬂammation of skin disorders such as contact
hypersensitivity, AD, and psoriasis [32]. Ultraviolet (UV)-induced
immunosuppression is partly explained by skin Treg cells. On
exposure to UV, keratinocytes express RANKL (receptor activator of
NF-kB ligand), which activates LCs to nurture Treg cells [32].
Despite difﬁculties in obtaining specimens, human skin Treg
cells have been studied [2,33]. Foxp3 is expressed in about 20% of
CD4T cells in adult human skin, while less than 10% in blood [33].
This observation is consistent with that in murine skin, where 25%
of CD4T cells are Foxp3+ in steady state and it can reach 60% under
inﬂammatory conditions ([34] and personal observation). Human
skin Treg cells are non-migratory being associated with hair
follicles [33]. Over time, they encounter with skin-associated
antigens, obtain effector-memory phenotype (CD45RO+ and high
levels of CTLA4, CD25, ICOS, CD27, and BCL2), and accumulate
gradually with age [33]. Few TCRb sequences are shared between
skin Treg cells and conventional skin memory T cells, indicating
that these two populations recognize different antigens [33]. Skin
Treg cells in psoriatic lesion are proliferative and express IL-17,
suggesting that they can be functionally defective in inﬂammatory
milieux [33]. It is unknown whether such Treg cells are equivalent
to non-suppressive cytokine-producing CD45RO+Foxp3lowT cells
observed in human blood [35].
On the other hand, a photo-convertible protein Kaede-based
cell-labeling method has shown shuttling of skin Treg cells
between skin and regional lymphnodes in both steady and
inﬂammatory state [8,32,36]. Migrant CD4T cells from the skin
contain a major population of Foxp3+ Treg cells that express high
levels of CD25, CD103, and GITR, and low level of CD62L, a cell-
surface phenotype suggestive of memory/effector cells [36]. These
Treg cells are potent suppressor in vitro and in vivo [36]. Further
study is needed to clarify the relationship between such migratory/
shuttling skin Treg cells and the skin resident Treg cells (the
majority of Treg cells observed in human skin).
Mechanism of Treg cell-mediated suppression is divided in
three: humoral factor-mediated suppression, cell-contact-depen-
dent suppression, and functional modiﬁcation of APCs (Table 5)
[32,37]. CTLA4 on Treg cells modiﬁes APCs, at least in mice, and
blockade of CTLA4 evokes tumor immunity in humans [32,38] [39].
Retinoic acid (RA) enhances differentiation of pTreg cells [32].
Topical or systemic retinoids—functional analogs of RA—ameliorate
acne vulgaris, photoaging, psoriasis, pityriasis rubra pilaris, cutane-
ous T cell lymphoma, and eczema. To what extent retinoids exert
their effects through modulation of Treg cells remains unknown.
5.7. Regulatory T cells without Foxp3
Tr1 or Th3 cells are CD4+ T cells that produce IL-10 or TGF-b,
respectively [14,40]. Antigen stimulation together with IL-10 and
vitamin D3 induces Tr1 cells. Type I interferon, IL-27, and ICOSinduce IL-10 production in T cells in a c-Maf dependent manner.
Nasal administration of anti-CD3 antibody induces Tr1 cells in
mice via AhR. Th3 cells, which may be a subset of pTreg cells, are
induced in animal models for oral tolerance.
LAG3 Treg cells are IL-10-producing CD4+CD25-LAG3+T cells
[41]. LAG3 (lymphocyte activation gene-3) attenuates CD4/MHC-
II-mediated T cell-activation. Expression of LAG3 and CD49b is a
marker for Tr1 cells [42]. Hence, LAG3 Treg cells may represent
naturally existing Tr1 cells, which had been once recognized as an
artiﬁcial subset induced in a test tube.
6. CD8T cells
CD8T cells, also known as killer or cytotoxic T lymphocytes
(CTLs), are the principal effector cells, which recognize antigens on
MHC-I and play roles in various skin diseases (Table 6). In steady
state, skin CD8T cells are essentially Trm cells, which reside in
epidermis and do not enter circulation [4]. CD8 Trm cells are not
only poised themselves to resume attack but also capable of
maximizing their function by summoning circulating memory T
cells to the site of virus reactivation or reentry [3].
Development of skin Trm cells is not fully understood. The skin
CD103+CD8+T cells, which develop in epidermis under the
inﬂuence of IL-15 and TGF-b, show a transcriptional proﬁle
shared with that of Trm cells [43]. CD8aa Trm cells persist in the
dermal–epidermal junction in the presence of reactivated human
herpes simplex virus 2 (HSV-2) [3]. It remains unknown whether
expression of CD8aa isoforms is related to repeated-exposure to
HSV-2. To understand the mechanism how skin Trm cells develop
leads to efﬁcient vaccine designing.
Effector CD8T cells are involved in various skin diseases
(Table 6). IL-17- or IL-22-producing CD8T (Tc17 or Tc22) cells
play roles in psoriasis. In addition to the eradication of virally
infected cells, CD8T cells induce apoptosis of tumor cells, grafted
allogeneic cells, or keratinocytes in the lesion of drug eruption.
Table 7
Characteristics of NKT cells in comparison with other lymphocytes.
Features NKT cells Conventional T cells NK cells
TCRa Invariant:
Va14 (mice)
Va24 (humans)
Diverse N/A
TCRb Variant but limited: Vb8 > 7 > 2 (mice)
Vb11 (humans)
Diverse N/A
Antigen or ligand Lipid (a-GalCer) Peptide Modiﬁed self
Restriction of antigen recognition CD1d MHC N/A
Development Thymus Thymus Extra-thymus and
thymus (minority)
Growth factor IL-15 IL-2
IL-15 (memory CD8T cells)
IL-15
Cytokine production Prompt Various Prompt
a-GalCer, alpha-galactosyl ceramide.
MHC, major histocompatibility complex.
N/A, not applicable.
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7. Innate-like abT cells
Innate-like abT cells include CD1d-restricted natural killer T
(NKT) cells, the CD8aa abT cells of intestine (in mice), and MR1-
restricted mucosal associated invariant T cells.
NKT cells are the best-characterized innate-like abT cells,
which develop in thymus, express invariant TCRs and NK1.1 (not
exclusively), and share characteristics with T cells and natural
killer (NK) cells (Table 7) [45]. They release wide range of cytokines
and chemokines, thereby affecting maturation of DCs that can
activate adaptive immunity, bridging the gap between innate and
adaptive immune system. NKT cells can enhance Th1- and Th2-
type responses. They are essential for development of contact
hypersensitivity by promoting survival and maturation of DCs in
draining lymphnodes in mice [46]. In contrast, NKT cells can also
mediate immunosuppressive effect of UV in mice [47]. These
incongruous functions of NKT cells may reﬂect their heterogeneity.Cancer
APC
STOP
STOP
CTLA4
PD-1
PD-1L
MHC
TCR
CD28
B7
B7
MHC
TCR
Ipilimumab
Lambrolizumab
Nivolumab
Tremelimumab
BMS-936559
Y
Y
Y
(1) Ear ly  stage
(2) Late stage
Fig. 2. Targets for tumor immunity. Activation of T cells is controlled in (1) early and
(2) late stage. (1) In early stage of T cell-activation, antigen-presenting cell (APC)
activates abT cells by peptide–MHC complex and the costimulator B7 (CD80 and
CD86), which engages TCR and CD28 on T cells, respectively. CTLA4 (CD152),
expressed on activated T cells or Treg cells, binds to B7 with 10 times higher afﬁnity
than CD28 does, thereby inhibiting T cell-activation. Anti-CTLA4 antibody, such as
ipilimumab and tremelimumab, binds to CTLA4 and interferes B7/CTLA4 axis, hence
enhancing T cell-activation. (2) In late stage, chronically activated T cells express
programmed cell death 1 (PD-1 or CD279), which binds to PD-1 ligand 1 (PD-L1 or
CD274) expressed on various tissues including cancer. PD-1/PD-L1 axis attenuates
effector function of T cells, thereby protecting tissues from collateral damage by
immune response. Anti-PD-1, such as lambrolizumab and nivolumab, or anti-PD-L1
BMS-936559 abrogates this inhibitory system to revive effector function of T cells.8. Manipulation of abT cells to treat skin inﬂammation and
cancer
T cells possess useful characteristics for treatments: selectivity
to antigens through TCR, modulatory effect on immune responses
through helper or regulatory T cells, and direct killing of target cells
(such as tumors) through CD8T cells.
Manipulation of Treg cells enables us to restore or preserve
tolerance to self-antigens, alloantigens, or foreign antigens.
Immunosuppression by transferred Treg cells (Tr1 cells) is more
robust than in vivo-transferred IL-10, an immunosuppressive
cytokine in a model of islet transplantation [48]. However, Treg
cell-therapy has several problems. Firstly, the effect of trans-
ferred cells must be sustained lifelong; otherwise the disease
may recur. Secondly, collecting adequate number of cells is
difﬁcult. Thirdly, safety of the injected Treg cells is not validated.
Finally, it is not established to monitor, prevent, and revise
uncontrolled cell proliferation, immunosuppression, and conse-
quent tumor development, all of which could occur by the
injected cells.
On the other hand, abrogation of inhibitory pathways of
immune system is becoming a promising approach to activating
antitumor immunity [39,49,50] (Fig. 2). Blocking of CD28-CTLA4
system by anti-CTLA4 antibody (ipilimumab or tremelimumab) or
PD-1 axis by anti-PD-1 (lambrolizumab or nivolumab) or anti-PD-
L1 (BMS936559) provided evidence of improvement in survival of
patients with metastatic melanoma.
9. Conclusion and perspective
Analyses of cell surface markers, cytokines, and transcription
factors have enabled us to discern various T cell-subsets, thereby
facilitating our understanding of immune function. Indeed,
immunotherapy targeting certain T cell-subsets has proven to
be successful in skin diseases such as psoriasis and malignant
melanoma. However, recent studies indicate that expression of
master regulators and cytokines often show ﬂexibility or plasticity
among the T cell-subsets [7]. This fundamental ﬁnding is
pragmatically important as well. Autoimmune diseases and
allergic inﬂammatory disorders are associated with various helper
T cell-subsets. If such subsets are ﬂexible, pathologically skewed
Th cells can be instructed to normal or benign subsets. On the other
hand, administration of Treg cells could be devastating, were these
cells converted to Th17 cells under inﬂammatory milieux.
Therefore, further study on mechanism of differentiation and
plasticity of T cell-subsets is essential to develop T cell-mediated
treatments.
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